BRIUMVI (ublituximab)
Relapsing Forms of Multiple Sclerosis
ApprovedCommercial
Key Facts
About TG Therapeutics
TG Therapeutics has successfully transitioned into a commercial entity with the FDA approval of BRIUMVI for relapsing multiple sclerosis, establishing a core revenue stream. The company's strategy is anchored on its proprietary glycoengineering platform, which enhances antibody potency to target CD20 on B-cells. This validated approach underpins its pipeline expansion into broader autoimmune and oncology indications, aiming to capture significant market share in competitive therapeutic landscapes.
View full company profileTherapeutic Areas
Other Relapsing Forms of Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| PONVORY® (ponesimod) | Juvise Pharmaceuticals | Approved |